Dissolution testing of oral modified-release dosage forms
Article first published online: 21 FEB 2012
© 2012 The Authors. JPP © 2012 Royal Pharmaceutical Society
Journal of Pharmacy and Pharmacology
Special Issue: Dissolution Testing. Guest Editors: Jennifer Dressman and Werner Weitschies
Volume 64, Issue 7, pages 944–968, July 2012
How to Cite
Garbacz, G. and Klein, S. (2012), Dissolution testing of oral modified-release dosage forms. Journal of Pharmacy and Pharmacology, 64: 944–968. doi: 10.1111/j.2042-7158.2012.01477.x
- Issue published online: 11 JUN 2012
- Article first published online: 21 FEB 2012
- Received October 13, 2011; Accepted December 12, 2011
- biorelevant dissolution;
- gastrointestinal stress;
- gastrointestinal transit;
- oral drug delivery
Objectives The in-vivo performance of oral modified-release dosage forms is determined by the interplay of various physiological- and dosage-form-derived parameters. Thus it is often a challenge to predict the in-vivo drug-release behaviour from modified-release dosage forms based solely on in-vitro release rates.
Key findings For a long time the most common procedure to obtain in-vitro/in-vivo correlations for modified-release formulations was to apply test conditions typically used for quality control on a retrospective basis. Such so-called ‘compendial approaches’ are typically not biorelevant with respect to volumes, composition and physicochemical properties of the test media and also do not take into consideration the mechanical and hydrodynamic forces that may influence dosage-form behaviour during passage through the gastrointestinal tract.
Summary This review provides an overview of physiological conditions relevant to in-vivo drug release and of dissolution models which, based on current scientific findings on human gastrointestinal physiology, have been developed to enable a better prediction of the in-vivo performance of oral MR dosage forms.